Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOBRAMUC: Shortened IV Tobramycin in Cystic Fibrosis
NCT03066453Phase 3Terminated
- Sponsor
- CHU de Lille
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tobramycin in cystic fibrosis (CF), sponsored by CHU de Lille. Started Jun 2017; status: terminated.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03066453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066453.